With a wide range of businesses joining the market and creating new products and services to meet the demands of women going through menopause, the menopause market is getting more and more competitive. As the industry expands, competition is likely to heat up, forcing businesses to stand out via innovation, efficacy, and safety in order to gain market share. 'Pfizer Inc.', 'Novo Nordisk A/S', 'Allergan plc', 'TherapeuticsMD Inc.', 'Mylan N.V.', 'Teva Pharmaceutical Industries Ltd.', 'Bayer AG', 'Merck & Co. Inc.', 'Johnson & Johnson', 'GlaxoSmithKline plc', 'Eli Lilly and Company', 'Amgen Inc.', 'AbbVie Inc.', 'Pfizer Inc.', 'Novartis International AG', 'Procter & Gamble Co.', 'Roche Holding AG', 'Sanofi SA', 'Serenity Pharmaceuticals LLC', 'Mithra Pharmaceuticals SA', 'In Feb 2022, Nestlé Health Science has completed the final acquisition of Vital Proteins, the one of the leading company in collagen in the United States and a lifestyle and wellness platform offering supplements, beverages and food products. Nestlé Health Science acquired a majority stake in Vital Proteins in 2020.', 'In 2022, TherapeuticsMD, Inc. (NYSE MKT: TXMD), an women’s healthcare company, announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR, an investigational bio-identical hormone therapy combination of 17ß-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause in post-menopausal women with an intact uterus'